CSIMarket
 


Kodiak Sciences Inc   (KOD)
Other Ticker:  
 

Kodiak Sciences Inc 's Leverage Ratio

KOD's quarterly Leverage Ratio and Total Liabilities, Equity growth


In Spite of the repayements of liabilities of -2.37%, in III Quarter 2023 ,Leverage Ratio deteriorated to 0.81 reached a new all-time high.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2023, 100 other companies have achieved lower Leverage Ratio than Kodiak Sciences Inc in the III Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 1233 to 1377 .

Explain Leverage Ratio?
Who are KOD Customers?
What are KOD´s Total Liabilities?


KOD Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -36.93 % -36.25 % -34.28 % -34.24 % -33.98 %
Y / Y Total Liabilities Change 0.32 % 0.08 % -2.04 % -4.33 % 5.42 %
Leverage Ratio MRQ 0.81 0.74 0.63 0.53 0.51
KOD's Total Ranking # 1377 # 1233 # 1146 # 1150 # 1163
Seq. Equity Change -10.65 % -13.78 % -9.99 % -9.04 % -9.68 %
Seq. Total Liabilities Change -2.37 % 1.39 % 7.5 % -5.73 % -2.6 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 101
Healthcare Sector # 525
Overall Market # 1377


Leverage Ratio Statistics
High Average Low
0.81 0.38 0.04
(Sep 30 2023)   (Dec 31 2019)




Financial Statements
Kodiak Sciences Inc 's Equity $ 302 Millions Visit KOD's Balance sheet
Kodiak Sciences Inc 's Total Liabilities $ 245 Millions Visit KOD's Balance sheet
Source of KOD's Sales Visit KOD's Sales by Geography


Cumulative Kodiak Sciences Inc 's Leverage Ratio

KOD's Leverage Ratio for the trailling 12 Months

KOD Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -36.93 % -36.25 % -34.28 % -34.24 % -33.98 %
Y / Y Total Liabilities TTM Growth 0.32 % 0.08 % -2.04 % -4.33 % 5.42 %
Leverage Ratio TTM 0.66 0.59 0.53 0.48 0.44
Total Ranking TTM # 4 # 1402 # 5 # 2 # 990
Seq. Equity TTM Growth -10.65 % -13.78 % -9.99 % -9.04 % -9.68 %
Seq. Total Liabilities TTM Growth -2.37 % 1.39 % 7.5 % -5.73 % -2.6 %


On the trailing twelve months basis Despite of the repayements of liabilities of -2.37% in the trailing twelve months ending in III Quarter 2023, Leverage Ratio improved to 0.66, above Kodiak Sciences Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry KOD recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 4, from total ranking in previous 12 month period at 1402.

Explain Leverage Ratio?
Who are KOD Customers?
What are KOD´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 1
Within the Market # 4


trailing twelve months Leverage Ratio Statistics
High Average Low
0.92 0.42 0.07
(Jun 30 2019)  




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Ladrx Corporation  2.18 $ 2.100  Millions$ 0.965  Millions
Curis Inc   2.00 $ 59.122  Millions$ 29.591  Millions
Meiragtx Holdings Plc  1.91 $ 175.308  Millions$ 91.886  Millions
Omega Therapeutics Inc   1.86 $ 141.765  Millions$ 76.043  Millions
Inhibrx Inc   1.85 $ 239.481  Millions$ 129.595  Millions
Estrella Immunopharma Inc   1.72 $ 17.281  Millions$ 10.069  Millions
Aptose Biosciences Inc   1.68 $ 13.100  Millions$ 7.776  Millions
X4 Pharmaceuticals Inc  1.55 $ 104.583  Millions$ 67.594  Millions
Orchard Therapeutics Plc  1.52 $ 122.008  Millions$ 80.258  Millions
Gilead Sciences Inc   1.50 $ 33,436.000  Millions$ 22,242.000  Millions
Cel sci Corporation  1.31 $ 17.313  Millions$ 13.215  Millions
Arcellx Inc   1.31 $ 348.090  Millions$ 266.128  Millions
Poseida Therapeutics Inc   1.27 $ 156.729  Millions$ 123.660  Millions
Adma Biologics Inc   1.22 $ 184.901  Millions$ 151.437  Millions
Autolus Therapeutics Plc  1.22 $ 220.089  Millions$ 180.518  Millions
Protalix Biotherapeutics inc   1.17 $ 44.820  Millions$ 38.247  Millions
Candel Therapeutics Inc   1.15 $ 26.539  Millions$ 23.022  Millions
Pharmacyte Biotech Inc   1.15 $ 42.110  Millions$ 36.768  Millions
Adaptive Biotechnologies Corporation  0.98 $ 355.950  Millions$ 361.637  Millions
Biogen Inc   0.95 $ 13,709.400  Millions$ 14,479.700  Millions
Sab Biotherapeutics Inc   0.86 $ 13.080  Millions$ 15.256  Millions
Century Therapeutics inc   0.81 $ 178.321  Millions$ 219.230  Millions
Kodiak Sciences Inc   0.81 $ 245.235  Millions$ 302.417  Millions
Avalon Globocare Corp   0.78 $ 13.145  Millions$ 16.823  Millions
Regenxbio Inc   0.75 $ 270.686  Millions$ 363.100  Millions
Gritstone Bio Inc   0.73 $ 53.805  Millions$ 73.982  Millions
Sana Biotechnology Inc   0.73 $ 265.588  Millions$ 365.852  Millions
Bluebird Bio Inc   0.71 $ 159.049  Millions$ 222.536  Millions
Xtant Medical Holdings Inc   0.68 $ 37.322  Millions$ 54.681  Millions
Beam Therapeutics Inc   0.66 $ 511.593  Millions$ 778.941  Millions

Date modified: 2023-11-16T18:23:33+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com